reports
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Fi...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today reported its fourth quarter and full year 2024 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. “Throughout 2024, we made substantial progress across multiple fronts, advancing our programs, expanding collaborations, and strengthening our balance sheet to support significant anticipated milestones,” stated ...
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 ...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provid...
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, announced today that the Company has initiated the DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. The DOSED study will evaluate the safety and utility of the Manual Inject Parenchymal Spinal Delivery System (MI PSD System), a novel delivery device developed to deliver directly to the area of injury in patients with spinal cord injury...
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual He...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Lifesciences Conference on February 11, 2025 at 12:40pm ET. The conference is being held virtually February 11-12, 2025. Interested parties can view a replay of the presentation on the section of Lineage’s website. Additional videos are available on the page of the Lineage websit...
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previ...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 million in gross proceeds at the closing of the first tranche in November 2024. Today, the Company received an additional $6 million in gross proceeds at the closing of the second tranche. In addition, the Company may receive up to an additional $36 millio...
Lineage Cell Therapeutics Issues Letter to Stockholders
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to shareholders highlighting the company’s recent achievements and outlook for 2025. Dear Fellow Shareholders, We hope you had a restful holiday season and wish you a happy new year. As we look at our plans for the new year, we want to update you on our recent progress and explain why we believe 2025 will be an exciting year for our company. As many of you know, Lineage is an emerging cell therap...
Lineage Cell Therapeutics Announces First Closing of up to $66 Million...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously announced registered direct offering for the purchase and sale of up to an aggregate of 39,473,688 of Lineage’s common shares and accompanying warrants (the “common warrants”) to purchase an aggregate of up to 39,473,688 of Lineage’s common shares at a combined purchase price of $0.76 per common share and accompanying common warrant. Lineage issued an aggregate of 31,578,951 ...
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Regis...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive agreements with certain healthcare focused institutional investors and with Broadwood Partners, L.P. (“Broadwood”), an affiliate of Neal Bradsher, a member of Lineage’s board of directors, for the purchase and sale of up to an aggregate of 39,473,688 of Lineage’s common shares and accompanying warrants (the “common warrants”) to purchase an aggregate of up to 39,473,688 of Lineag...
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. “We were delighted to see our partners’ continued commitment to the OpRegen program, in this instance by seeking and successfully obtaining RMAT designation,” stated Brian M. Culley, Lineage CEO. “We believe OpRegen continues ...
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Resul...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 14, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2024 financial and operating results and to provide a business update. Interested...
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual H...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the , in a fireside chat hosted by Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research. Lineage’s fireside chat will be available for viewing on Tuesday, October 15, 2024, at 11:00 a.m. ET, for registered conference attendees. About the Maxim Group 2024 Healthcare Virtual Summit Maxim Senior Analysts wil...
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International S...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the (ISSCR) , PSC-Derived Cell Therapies: Clinical Advances, NextGen Technologies, and the Path to Success. Mr. Culley has been invited to participate as part of a panel entitled “Clinical Trial Updates: PSC-Derived Therapies of the Eye,” on Wednesday, October 2nd, 2024, from 10:30 am to 12 pm CEST. The panel is being chaired by , S...
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transp...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that preclinical results with ReSonance (ANP1), the Company’s auditory neuronal cell transplant for the treatment of hearing loss, were presented at the by Ofer Wiser, Ph.D. Senior Scientist, Technological Innovation at Cell Cure Neurosciences, Inc., the Company’s Israel-based subsidiary, which is responsible for research, process development, and good manufacturing practice (GMP) production. “We are excited t...
Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the being held on Thursday, August 15, 2024. Lineage’s will be available for viewing on-demand, beginning on Thursday, August 15, 2024, at 7:00am ET, for registered conference attendees. Interested parties can also register to view a replay of the presentation on the section of Lineage’s website. Additional videos are available ...
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Result...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its second quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. “The second quarter was highlighted by clinical and preclinical execution alongside expanded awareness and data updates on our lead program,” stated Brian M. Culley, Lineage CEO. “As the cell transplant field expands and cont...
Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Resu...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 8, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2024 financial and operating results and to provide a business update. Interested pa...
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® In...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000® Index, effective after the U.S. market opens on July 1, 2024, as part of the 2024 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, 2024, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for ...
Lineage to Present at 2024 BIO International Convention
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the , on Tuesday June 4th, 2024, at 2:30pm in Theater 3. Company representatives are also hosting meetings with potential partners and collaborators to discuss opportunities for strategic alliances across Lineage’s novel pipeline of cell therapy transplant programs. The BIO International Convention is the world’s largest gathering of the biotechnology ind...
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Sy...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its ("2nd SCIIS"). The 2nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advocacy organizations, and the investment community, in order to discuss perspectives on current and future treatment alternatives, im...
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. “The quarter was highlighted by significant milestones and data updates on our lead program,” stated Brian M. Culley, Lineage CEO. “A key area of attention for investors is our partnership with Roche and Genentech, and we are pleased to anno...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.